Biotech News

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Dyne Therapeutics (DYN)Dyne TherapeuticsEarnings

- Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 skip amenable Duchenne muscular dystrophy (DMD); additional long-term data to be

Related news

Dyne Therapeutics

Oligonucleotide Therapeutics Dyne Therapeutics develops targeted oligonucleotide medicines for genetically driven muscle diseases. Its FORCE platform links therapeutic payloads to antibodies intended to improve delivery into muscle tissue. Duchenne Muscular Dystrophy Z-rostudirsen is designed for patients with Duchenne muscular dystrophy...

Recent company news

Stock data

Close
26.10 USD
Market cap
2.85B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States